Why the study?
Does an intensive sequenced adjuvant chemotherapy regimen (CMFVP followed by doxorubicin) improve disease-free survival and have acceptable toxicity in women with node-positive, stage II breast carcinoma?
Does an intensive sequenced adjuvant chemotherapy regimen (CMFVP followed by doxorubicin) improve disease-free survival and have acceptable toxicity in women with node-positive, stage II breast carcinoma?
Adjuvant CMFVP followed by intensive doxorubicin is feasible and yields an 80.5% chance of disease-free survival at 42 months in women with node-positive stage II breast cancer.
Answers are grounded in this paper and cite their sources.
Should not change practice; hypothesis-generating for sequenced adjuvant regimens in node-positive breast cancer.
Twenty-two women (17 pre- and 5 postmenopausal) with nodepositive, stage II breast carcinoma were treated with adjuvant chemotherapy consisting of 16 weeks of intensive CMFVP (cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone) administered in the original dose and schedule of the "Cooper regimen," followed by four monthly, 3-day cycles of escalating doxorubicin. Toxicity was related primarily to myelosuppression associated with the doxorubicin component of the treatment regimen. All patients recovered without sequelae. No patient developed significant cardiac toxicity. With a median follow-up of 43 months (range: 20-89 months), two postmenopausal patients and one premenopausal patient have relapsed at 35, 37, and 42 months, respectively. By Kaplan-Meier survival analysis, there is an 80.5% chance of disease-free survival to 42 months. The feasibility of administering adjuvant CMFVP followed by intensive doxorubicin has been established. The pilot results warrant comparative trial with the best of current regimens.
No takes yet. Share an insight, caveat, or question.
Bhardwaj et al. (1993) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: